Abstract:Background Idiopathic pulmonary fibrosis (IPF) is a devastating disease that probably involves several genetic loci. Several rare genetic variants and one common single nucleotide polymorphism (SNP) of MUC5B have been associated with the disease. Our aim was to identify additional common variants associated with susceptibility and ultimately mortality in IPF.Methods First, we did a three-stage genome-wide association study (GWAS): stage one was a discovery GWAS; and stages two and three were independent case-control studies. DNA samples from European-American patients with IPF meeting standard criteria were obtained from several US centres for each stage. Data for European-American control individuals for stage one were gathered from the database of genotypes and phenotypes; additional control individuals were recruited at the University of Pittsburgh to increase the number. For controls in stages two and three, we gathered data for additional sex-matched European-American control individuals who had been recruited in another study. DNA samples from patients and from control individuals were genotyped to identify SNPs associated with IPF. SNPs identified in stage one were carried forward to stage two, and those that achieved genome-wide significance (p<5 x 10(-8)) in a meta-analysis were carried forward to stage three. Three case series with follow-up data were selected from stages one and two of the GWAS using samples with follow-up data. Mortality analyses were done in these case series to assess the SNPs associated with IPF that had achieved genome-wide significance in the meta-analysis of stages one and two. Finally, we obtained gene-expression profiling data for lungs of patients with IPF from the Lung Genomics Research Consortium and analysed correlation with SNP genotypes.Findings In stage one of the GWAS (542 patients with IPF, 542 control individuals matched one-by-one to cases by genetic ancestry estimates), we identified 20 loci. Six SNPs reached genome-wide significance in stage two (544 patients, 687 control individuals): three TOLLIP SNPs (rs111521887, rs5743894, rs5743890) and one MUC5B SNP (rs35705950) at 11p15.5; one MDGA2 SNP (rs7144383) at 14q21.3; and one SPPL2C SNP (rs17690703) at 17q21.31. Stage three (324 patients, 702 control individuals) confirmed the associations for all these SNPs, except for rs7144383. Linkage disequilibrium between the MUC5B SNP (rs35705950) and TOLLIP SNPs (rs111521887 [r(2)=0.07], rs5743894 [r(2)=0.16], and rs5743890 [r(2)=0.01]) was low. 683 patients from the GWAS were included in the mortality analysis. Individuals who developed IPF despite having the protective TOLLIP minor allele of rs5743890 carried an increased mortality risk (meta-analysis with fixed-effect model: hazard ratio 1.72 [95% CI 1.24-2.38]; p=0.0012). TOLLIP expression was decreased by 20% in individuals carrying the minor allele of rs5743890 (p=0.097), 40% in those with the minor allele of rs111521887 (p=3.0 x 10(-4)), and 50% in those with the minor allele of rs5743894 (p=2.93 x 10(-5)) compared with homozygous carriers of common alleles for these SNPs.Interpretation Novel variants in TOLLIP and SPPL2C are associated with IPF susceptibility. One novel variant of TOLLIP, rs5743890, is also associated with mortality. These associations and the reduced expression of TOLLIP in patients with IPF who carry TOLLIP SNPs emphasise the importance of this gene in the disease.

The MUC5B rs35705950 allele is a cooperator in familial pulmonary fibrosis.

Familial Pulmonary Fibrosis: Clinical, genetic and radiological characterization

MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis

A meta-analysis examining the association between the MUC5B rs35705950 T/G polymorphism and susceptibility to idiopathic pulmonary fibrosis

Association Between the MUC5B Promoter Polymorphism Rs35705950 and Idiopathic Pulmonary Fibrosis

Methylenetetrahydrofolate reductase polymorphism in childhood primary focal segmental glomerulosclerosis.

The MUC5B promoter variant results in proteomic changes in the non-fibrotic lung

Clinical Features And Genetic Characterization Of Familial Pulmonary Fibrosis In A Chinese Family

Polymorphisms and haplotypes of TOLLIP and MUC5B are associated with susceptibility and survival in patients with fibrotic hypersensitivity pneumonitis

Bleomycin-Induced Pulmonary Fibrosis in Transgenic Mice Carrying the Human MUC5B rs35705950 Variant

MUC5B rs35705950 Promoter Variant Is Associated with Usual Interstitial Pneumonia in Patients with Antisynthetase Syndrome

A Test to Comprehensively Capture the Known Genetic Component of Familial Pulmonary Fibrosis

FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease

Data from Cumulative Effect of Multiple Loci on Genetic Susceptibility to Familial Lung Cancer

The relationship between MUC5B promoter, TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort

The Integrated Stress Response Links Muc5b to Pulmonary Fibrosis

Genetic Variants Associated with Idiopathic Pulmonary Fibrosis Susceptibility and Mortality: A Genome-Wide Association Study

Gene polymorphisms and risk of idiopathic pulmonary fibrosis: a systematic review and meta-analysis

Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine

Mucin 5B promoter polymorphism is associated with susceptibility to interstitial lung diseases in Chinese males.

The prevalence of MUC5B variant and survival of patients with interstitial lung disease in Ireland: A multi-centre cohort study